• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    device and method for corneal release of riboflavin by iontophoresis for the treatment of keratoconus, comprising an ocular iontophoresis device for releasing any ionized drug solution, such as riboflavin solution, to the cornea comprises, in combination: a reservoir (8) containing a riboflavin solution that is suitable for merely being placed in the eye; an active electrode (2) disposed on or in the reservoir (8); and a passive electrode suitable to be positioned on the individual's skin, or elsewhere on the body, preferably in locations close to the eye, such as the forehead, cheek or neck; means (10) for irradiation of the corneal surface with adequate light, such as uv light, for obtaining cross-connection of the cornea after the drug or riboflavin is released; where said reservoir (8) and said active electrode (2) are transparent to uv and / or ir light; method for delivering any ionized drug solution, such as riboflavin solution, to the cornea for treatment of keratoconus or any other ectatic corneal disease, or for strengthening the stromal structure of the cornea by means of an ocular iontophoresis device according to the preceding claims, presenting the following steps: - positioning of said iontophoretic device in the eye to be treated, the device comprising a reservoir containing the riboflavin solution: - directing the movement of the solution by an applied cathodic current for 0.5 to 5 minutes , at an intensity less than 2 ma; - irradiation, immediately after the end of the current application, of the corneal surface with uv light for 5 to 30 minutes at a power of 3 to 30 mw / cm2, thus obtaining the cross-connection of the riboflavin cornea.
    公开号:BR112013010050B1
    申请号:R112013010050-8
    申请日:2011-01-12
    公开日:2021-03-30
    发明作者:Fluvio Foschini；Pierre Roy；Giovanni Cavallo；Giulio Luciani；Edoardo STAGNI
    申请人:Sooft Italia Spa；
    IPC主号:
    专利说明:

    [001] The present patent application describes a new device for iontophoresis for the release of ophthalmic compositions (in particular eye drops), preferably containing riboflavin, designed to wet the stroma of the cornea without having to proceed, to obtain the said imbibition, for the removal of the corneal epithelium (removal of the epithelium) in the practice of treating keratoconus, or other ectatic disorders of the cornea, by cross-linking the cornea of the appropriate ophthalmic composition.
    [002] Keratoconus is a degenerative disease in the eye, in which structural changes within the cornea make it thinner and change to a more conical shape than its normal gradual curve. Keratoconus is a genetic disease that consists of progressive non-inflammatory dystrophy affecting approximately 50 people to 100,000 each year, usually young people between 10 and 20 years of age. As the frequency of the disease is higher among women, the etiology of keratoconus seems to be related to dysfunctions of the endocrine glands (pituitary and thyroid). It can affect both eyes in approximately 85% of cases and has an evolution that can vary in each individual.
    [003] After the onset of the symptoms of the disease, an irregular curvature appears that modifies the refractive power of the cornea, producing image distortions and a confused near and distant vision. The patient complains in any case of a vision reduction, above all the distant vision. The vision continues to regress irreversibly, with a consequent need for frequent exchange of glasses and, for this reason, it can first be mistaken for myopia associated with astigmatism.
    [004] Due to the congenital structural weakness of the stroma of the cornea due to the aforementioned disease, the cornea tends after a few years to gradually wear out and lose thickness towards the apex. Then there is the irregular curvature of the cornea, which loses its spherical shape and takes the shape of a cone (keratoconus).
    [005] Using a biomicroscope, a considerable reduction in corneal thickness can be seen in the upper part of the keratoconus. Over time, the upper part of the keratoconus becomes opaque due to a change in the nutrition of that part of the cornea, which in the most acute forms may present a corneal curvature of over 62D and reach a corneal thickness of up to 446 μm (the normal thickness of the central cornea is 500 - 700 μm).
    [006] If the disease is not treated, the upper part may form an ulcer with consequent perforation of the cornea; pain, lacrimation and spasm of the eyelids occur. These changes in the cornea due to keratoconus produce a change in the disposition of the corneal protein, causing micro scars that distort the images and, in some cases, prevent the passage of light, which makes the person feel dizzy, especially when the sun is close to the horizon (sunrise and sunset).
    [007] As already mentioned, to correct vision it is necessary to change glasses frequently. Only after wearing glasses is unsatisfactory, rigid contact lenses in more intermediate formats can be applied.
    [008] The real problem arises when the cornea affected by keratoconus undergoes a considerable thinning or if the healing occurs after lacerations of the corneal surface, making it necessary even a corneal transplant (keratoplasty).
    [009] In 2002, the so-called lamellar keratoplasty was introduced in Italy for the treatment of keratoconus, through which, in practice, the cornea is replaced not without its entirety, but only in the outer thickness, that is, the affected part by the disease.
    [0010] However, already in 1997 in Germany, at the Carl Gustaw Carus University eye clinic in Dresden, a new, safer and less invasive technique was developed, designated as "corneal cross-linking" (CXL), which it uses, especially , riboflavin, activated by a UV laser; in 2005, this technique was also tested in Italy and is currently widely used successfully in several Italian eye clinics.
    [0011] Corneal cross-linking is a minimally invasive method, which uses riboflavin activated by a UV laser (365-370 nm); the method is painless and is performed in hospitals. Cross-linking enables the reinforcement of the corneal structure affected by keratoconus through internal interlacing and increased connections (cross-linking) between the corneal collagen fibers. Clinical studies have proven that CXL is capable of reducing the astigmatism associated with keratoconus, as well as reducing or interrupting the evolution of the pathology, thus avoiding the need for corneal transplantation. In addition, other disorders characterized by corneal ectasia benefit from treatment using the cross-linking method.
    [0012] Corneal cross-linking is usually performed by applying local anesthesia to the cornea to perform abrasion of the corneal epithelium (removal of the epithelium) with a diameter of 8-9 mm. This is followed by frequent instillation of an ophthalmic solution based on 0.1% riboflavin for 15 minutes, followed by irradiation with ultraviolet emitter (UV-A) for 30 minutes with instillation of riboflavin solution throughout the irradiation operation.
    [0013] Riboflavin (molecular weight 376, unsatisfactory solution in water), more preferably riboflavin sodium phosphate (molecular weight 456, negatively charged), commonly used in corneal cross-linking, is a photosensitive hydrophilic molecule and photo polymer with a low capacity diffusion through the epithelium and therefore reaches the stroma of the cornea.
    [0014] Therefore, it is necessary to facilitate its absorption and complete impregnation of the corneal stroma before starting irradiation with UV-A, removing the corneal epithelium (removal of the epithelium). This procedure can create, even if rarely, complications at a level of the cornea and pain, in addition to being a method that makes the job of the ophthalmologist more difficult.
    [0015] It would therefore be desirable to improve the absorption of riboflavin, without having to remove the corneal epithelium, thereby obtaining a non-invasive crosslinking of the cornea with elimination or reduction of anesthesia and, consequently, a quick cure without pain or possible complications.
    [0016] Iontophoresis is known as a non-invasive method that allows the penetration of high concentration of ionized molecules, such as medicines, into living tissues carried by an electric current, in fact, the application of a current to an ionizable substance increases its mobility along a biological surface. Three main forces govern the flow caused by the current. The primary force is electromechanical repulsion, which drives species of the same charge through tissues. When an electric current passes through an aqueous solution containing electrolytes and a charged material (for example, the active pharmaceutical ingredient), several events occur: (1) the electrode generates ions, (2) the newly generated ions approach / they collide with the charged particles (typically the drug being released), and (3) electropulsion between the newly generated ions forces the charged dissolved / suspended particles to and / or across the adjacent surface (tissue) to the electrode.
    [0017] The continuous application of electric current takes the active pharmaceutical ingredients significantly further into the tissues than is achieved with simple topical administration. The degree of iontophoresis is proportional to the current applied and the treatment time.
    [0018] Iontophoresis occurs in water-based preparations, where ions can be readily generated by electrodes. Two types of electrodes can be used to produce ions: 1) inert electrodes and 2) active electrodes.
    [0019] Each type of electrode requires an aqueous medium containing electrolytes. Iontophoresis with an inert electrode is governed by the extent of water hydrolysis that an applied current can produce. The electrolysis reaction yields OH- hydroxide ions (cathodic) or H3O + hydronium (anodic). Some formulations contain buffers, which can mitigate the pH changes caused by these ions. The presence of certain buffers introduces charged ions that can compete with the drug product for electrolytically generated ions, which can decrease the release of the drug product (and therefore increase the required application time). The electrical polarity of the medicated delivery electrode depends on the chemical nature of the medicated product, specifically its pKa (s) / isoelectric point and the pH of the initial dosing solution. The electromechanical repulsion between the ions generated through electrolysis and the charge of the medicated product that primarily takes the medicated product to the tissues. Therefore, iontophoresis offers a significant advantage over the application of topical drugs, since it increases the absorption of the drug. The rate of drug release can be adjusted by varying the current applied by the person with skill in the technique.
    [0020] Due to the highly effective mode of administration of the iontophoresis process, ophthalmologists have long recognized the value of iontophoresis in the release of healing molecules to the eye and in the treatment of ocular pathologies, since the iontophoretic process does not allow only faster application of the drug, but also allows a more localized and highly concentrated application of the drugs.
    [0021] Several iontophoretic ocular devices have been developed, reported in the literature and known by the prior art.
    [0022] US patent 3,122,137 filed on 10/30/1961 describes an iontophoretic ocular device that consists of a glass structure for the eyes made of non-conductive materials and incorporating a current source adapted to be supported by the area around the eye socket, so that the device cannot be in direct contact with the surface of the eyes. Said device does not have a precision of administration due to its rudimentary characteristics of structure and design.
    [0023] US patent 4,564,016 filed on 08/13/1984 describes an equipment containing a part in connection with the eye, consisting of a small application surface (1mm in diameter) applied to the sclera and allowing very high densities of currents for focal iontophoresis. The referred equipment and the relative method are particularly adapted to introduce ionized drugs into the back of the eye along the cell barriers protecting the retina, such as the conjunctival epithelium and the pigment epithelium, but the current applied by this method is certainly toxic to related tissues.
    [0024] More recently, the US patent 6,319,240 filed on 05/25/1999 proposes an improvement of the previous equipment characterized by the presence of a containment element, such as a sealed reservoir applied to the sclera (with a semipermeable membrane on the surface of application) under the eyelid, filled with the medication released under the influence of the electric current.
    [0025] The peculiar feature of the invention described in US patent 6,442,423 filed on 02/05/1991 is an applicator containing a receiving part containing a replaceable hydrogel carrier that is loaded with the drug. The solution presented by this patent application guarantees that the fluid medical solution is kept in contact with the eye during the iontophoresis process, in fact the maintenance of fluids to guarantee its contact with the eye surface is complicated, since that fluids leak and form bubbles that reduce the effectiveness of the iontophoretic process.
    [0026] The invention described in US patent 6,154,671 filed on January 4, 1999 relates to a device for transferring active pharmaceutical ingredients to the eyeball by iontophoresis characterized by an active electrode in the reservoir, which is a surface electrode disposed towards the ocular tissues in the peripheral part of the cornea. In this case, the transfer achieved by this system takes place through one or more ocular tissues in the peripheral part of the cornea over a large area of application.
    [0027] The problem of the invention presented by the US patent 7,164,943 filed on 06/03/2004 presents an irritation-reducing ocular iontophoresis device provided with the aforementioned characteristics allowing the reduction of the application time in the eyes and the consequent irritation .
    [0028] In addition, following technical advances in the field of iontophoresis that have occurred in recent decades, currently in research and development and focused especially on the various possible formulations for release by ocular iontophoresis and their methods of use.
    [0029] The use of ophthalmic compositions, possibly associated with riboflavin for crosslinking the cornea in the treatment of keratoconus or other corneal ectatic disorders has been described and is the subject of international patent application PCT / IT2009 / 000392, and the application of relative priority of patent RM2008A00472. The compounds revealed based on riboflavin facilitate epithelial absorption associated with corneal cross-linking (CXL), avoiding resorting to the removal of the corneal epithelium, allowing a non-invasive removal of the cornea or reduction of anesthesia and, consequently, a quick cure without pain or possible complications for patients.
    [0030] It is also known that, from patent application WO2007 / 025244, a kit cleaning system and method is presented. One embodiment of the present invention has a photosensitizing solution provided by a pressurized nozzle to the target site. A specific application of the solution is a target site on the oral or skin surface. The photosensitizing solution is illuminated with sensitization light creating reactive chemical species. Pressure and a solvent having a high concentration of oxygen or oxygen species that improve the efficiency of destroying pathogens. Methods of using the system within the oral cavity are also presented.
    [0031] In this document, the active electrode is not transparent under UV light, visible light or infrared light.
    [0032] However, despite the most recent advances in the relevant field, there is still a need for more efficient delivery systems for the release of ophthalmic compounds to moisten the corneal stroma in the practice of cross-linking for the treatment of keratoconus, and ophthalmic compositions suitable for the treatment of keratoconus specifically formulated to be adapted for the most efficient application of corneal iontophoresis.
    [0033] New devices and methods are described using iontophoresis to actively release a riboflavin-based compound into the mammalian eye. The method — and the device, according to the present application for a patent, are focused on the development and uses of riboflavin formulations to be employed in performing cross-linking for the treatment of keratoconus.
    [0034] Riboflavin sodium phosphate, commonly used in corneal cross-linking, is a low molecular weight molecule, soluble in water and negatively charged. This set of characteristics makes it a potential target for cathodic iontophoresis, as shown in Figure 1.
    [0035] As already indicated above, iontophoresis is substantially the promotion of movement of a charged substance along a biological membrane through the application of a low electric current forming an electric field. It is the result of three transport mechanisms: chemical, electrical and electro-osmotic flows, which are explained in the Nernst-Planck equation below: Fluxototal = Fluxopassive + Fluxelectric + Fluxototal Fluxototal = -D / (dc / dx) + (DzVFCi) / (kT) +/- CU Where: - D Diffusion coefficient (characteristic of the biological membrane) - dc / dx Concentration gradient - z valence - V Electric field - F Faraday constant - k Boltzmann constant - T Temperature - Ci Concentration of ionized medicine - C Containment of medicine - u Convective flow of water
    [0036] We assume, for simplicity, that the passable contribution is negligible (see Prausnitz "Permeability of Cornea, Sclera, and Conjunctiva: A Literature Analysis for Drug Delivery to the Eye", Journal of Pharmaceutical Sciences 1/1479 Vol. 87, No 12, December 1998 for experimental values).
    [0037] The Electrorepulsion Flow depends on the charge (valence), the electric field V and the concentration Ci, which are proportional to the current density I and inversely proportional to the mobility of ions in the fluid u (I = u.z.V.Ci). The mobility of the ion depends on several factors, such as concentration, interaction between ionic species and between the ions and the solvent molecule, the size of the molecule of the charged drug, the polarity of the solvent, ... etc.
    [0038] Electro-osmotic flow occurs when an electric field is applied across a membrane and produces a bulk movement of the solvent itself that transports ionic or neutral species with solvent flow. It is proportional to the concentration of ionic and neutral species of the drug.
    [0039] From this, we can simplify the Nersnt-Planck equation as follows: Fluxototal = + (D. I .Ci) / (u. K.T) +/- C.U
    [0040] One of the concerns is the direction of the electro-osmotic flow and the relative importance of the flow compared to the passive and repulsion flow. The electro-osmotic flow is in the direction of the membrane loading counterions. At physiological pH (7.4), the skin, like most biological membranes including the cornea and sclera, is negatively charged. Therefore, the electro-osmotic flow increases the anodic (+) release of positively charged medication while the cathodic (-) release of negatively charged medication is delayed.
    [0041] With low pH, over pI, the isoelectric value of the cornea and sclera is considered 4 (see Huang et al, Biophysical journal 1999) and comparable to the pI values of the skin surface that vary from 3 to 4, the surface turns positive and reverse electro-osmotic flows. This explains the importance of performing a buffer, which in addition to protecting against conjunctival and corneal damage (the eye can tolerate a wide range of pH and ophthalmic solutions can vary from pH 4.5 - 11.5, but the useful range to avoid corneal damage it is 6.5 to 8.5), but it keeps the relative contribution of each flow at a constant level. It also guarantees a stable number of ionic species in the solution if the duration of the applied current is kept low.
    [0042] In view of the above, it is the aim of the present patent application to present an innovative iontophoresis device for the release of specific product formulations adapted for corneal wetting associated with cross-linking and subsequent UV treatment for obtaining bonding cross-section of corneal stroma proteins.
    [0043] The present invention is defined by claim number 1.
    [0044] Therefore, in a first aspect of the present patent application there is an ocular iontophoresis device for releasing riboflavin solution to the cornea, the device comprising: - a reservoir containing the appropriate riboflavin solution to be placed in the eye ; - an active electrode disposed in the reservoir; e - a passive electrode
    [0045] The passive electrode is placed on the individual's skin, or elsewhere on the body, preferably close to the eyes, such as on the forehead, cheeks or neck.
    [0046] Also presented is a method of treating keratoconus by ocular iontophoresis, which is not part of the invention, where, to release the riboflavin solution to perform corneal cross-linking, an iontophoretic device is positioned in the eye, the device comprising a reservoir containing the riboflavin solution with an initial pH of about 4-5, without buffer or with minimum buffer content, the reservoir being suitable to be positioned in the eye, and containing an active electrode positioned in the reservoir, and an electrode passive; the movement of the solution is guided by a cathodic current applied for 0.5 to 5 minutes, preferably 1 to 3 minutes, at an intensity of 2 mA, preferably 1 mA.
    [0047] In addition, in a third aspect, an ocular iontophoresis device is presented comprising: a) a reservoir containing the riboflavin solution, the reservoir extending along a surface directed to cover a part of the surface of the eyeball , and fed with a cleaning element to remove excess riboflavin solution at the end of the iontophoresis procedure, b) an active electrode structure made of material transparent to UV light associated with the reservoir, in order to provide a directed electric field through the riboflavin solution and towards a surface of the eye, where the riboflavin solution is released in a transcorneal manner through the surface of the eye by iontophoresis, the transparent material allowing the irradiation of the riboflavin solution immediately after the current application.
    [0048] According to the present patent application, the electrode structure is made of electrically conductive material, such as stainless steel, ferrous materials, non-ferrous materials, such as aluminum, copper, tungsten, silver, gold, carbon, polymers conductive (naturally conductive or charged with conductive particles).
    [0049] The electrode can be made of mesh, a perforated plate with small holes or any semicontinuous structure with holes, large enough to allow UV light to be transmitted.
    [0050] Ideally, the electrode can be made of a transparent and continuous plastic part, puffed on the side of the reservoir with a mesh with or thin lines of conductive materials, which can be printed with screen printing or pad printing techniques.
    [0051] The electrode is connected to a direct current generator releasing a direct current of 0.5 to 2 mA at a voltage adapted to the body and impedance of the riboflavin solution. The generator is, in turn, connected to a return electrode positioned at another location on the body to close the electrical circuit.
    [0052] The electrode of the device is ideally positioned at a distance of 1 to 6 mm from the central cornea or, preferably, from 4 to 5 mm.
    [0053] From the experiment, it was observed that, during the time of iontophoresis application, the pH increases only near the electrode and, therefore, away from the surface of the eye. As a consequence, according to the present patent application, the value of the change in pH on the surface of the eye can be controlled by modifying the distance of the electrode to the surface of the eye.
    [0054] The distance from the electrode to the surface of the eye is increased for a longer time of iontophoretic application, thereby minimizing the increase in pH on the surface of the eye.
    [0055] In a particular configuration of the present application, the electrode structure has a mesh or surface comprising a sufficient number of holes for the electrode to be semitransparent to UV at the appropriate wavelength of 365 nm (Figure 4) .
    [0056] In another particular configuration, the electrode structure has an annular shape, with a divergent transparent lens at its center, allowing an illumination surface of 8 mm in diameter at a distance of 10 mm (Fig. 5).
    [0057] In another particular configuration, the electrode structure is a disk, surrounded by a diverging annular lens allowing an illumination surface of 8 mm in diameter at a distance of 10 mm (Figure 6).
    [0058] In another variant, the electrode structure is a 10 mm diameter disk, surrounded by a diverging annular lens allowing an illumination surface of 8 mm at a distance of 10 mm, the walls of the device containing an alpha angle, between 60 ° and 120 °, preferably between 30 ° and 20 ° to avoid an excess of incident light refraction (Figure 7).
    [0059] According to the present patent application, the iontophoresis device has a circular shape with an internal diameter of 8-12 mm, preferably 10 mm, made of non-electrical conductive materials, such as plastic. The proximal side of the device, in contact with the cornea or limbus in the peripheral part of the cornea, can be made of a different material, such as an elastomeric material. This feature makes it possible to accommodate small changes in the geometry of the eye so that it can fit perfectly on the surface of the eyes, avoiding fluid leaks.
    [0060] In the peripheral part of the device structure, a second circular wall with an open end on the side of the eye and a closed end on the side of the electrode, and intends to form a vacuum of light in the external annular chamber (see Figure 1).
    [0061] The distal surface of this annular chamber corresponds to the pars plano area of the eye, with an internal diameter of 12 mm and an external diameter of 18 mm, preferably 16 mm, or more preferably 14 mm.
    [0062] When the device is positioned in the eye, a light vacuum is set up in the chamber to keep the device fixed during application. ELECTRODE STRUCTURE:
    [0063] The same plastic material, such as polymethacrylate, polycarbonate, cycloolefin, polymethylpentane, polystyrene, is used to create the shape of a divergent or converging lens, allowing central illumination of the cornea in a diameter of 8 to 10 mm.
    [0064] The lens can be positioned centrally or peripherally on the electrode, or around the electrode. When the lens is positioned around the electrode, the electrode surface is maximized.
    [0065] The structure of the device with its walls and the electrode forming a reservoir, with an open end in contact with the eye and a closed end where the electrode is located.
    [0066] For greater advantage, the walls of the device can be made with a non-transparent material in a given wavelength treatment to avoid irradiation from the peripheral part of the cornea or the structure of the limbus.
    [0067] The time of application of the device in the cornea consists of 0.5 to 5 minutes of application of current, immediately followed by UV irradiation for 5 to 30 minutes at a power of 3 to 30 mW / cm2.
    [0068] Before applying the light, the riboflavin content in the reservoir is purged.
    [0069] Finally, it is useful to highlight that the device, according to the present patent application, can be applied in any ionized solution, positively or negatively charged, which would induce collagen cross-linking under application of UV light and / or visible light and / or IR light. LIST OF REFERENCES IN THE DRAWINGS: 1. inner wall 2. active electrode 3. annular chamber 4. spring 5. syringe 6.. non-return valve 7.. transparent plastic 8.. reservoir 9. means for irradiating the corneal surface 10. lens Legend of Figures 2 0 - UV 30 - Eye
    权利要求:
    Claims (24)
    [0001]
    1. “OCULAR IONTOPHORESIS DEVICE TO ADMINISTER ANY IONIZED MEDICINAL SOLUTION”, such as a solution of riboflavin, in the cornea, comprising in combination: - a reservoir (8) adapted to contain a riboflavin solution that is adapted to be simply placed in the eye; - an active electrode (2) disposed in or on the reservoir (8); - a passive electrode suitable to be placed on the subject's skin, somewhere on the body, preferably in the immediate vicinity of the eye, such as on the forehead, face or neck; - means (10) for irradiating the corneal surface with suitable light, such as UV light, to obtain corneal crosslinking after administration of the drug or riboflavin; characterized in that said reservoir (8) and said active electrode [ai] (2) are transparent to UV light and / or visible light and / or IR light.
    [0002]
    2. "OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claim 1, characterized by comprising means to provide a cathodic current having an intensity of 2 mA, preferably 1 mA.
    [0003]
    3. "OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claims 1 or 2, characterized by comprising means to provide a cathodic current for 0.5 to 5 minutes, preferably 1 to 3 minutes.
    [0004]
    4. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that said reservoir (8) containing the riboflavin solution extends over a surface that covers a part of the surface of the eyeball and be provided with a washing element to remove excess riboflavin solution.
    [0005]
    5. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that said active electrode (2) has a structure made of material transparent to UV light associated with the reservoir 8 to provide an electric field directed through the riboflavin solution and towards a surface of the eye, in which the riboflavin solution is administered transcorneally through the surface of the eye by iontophoresis, the transparent material being adapted to allow the irradiation of the riboflavin solution.
    [0006]
    6. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that the active electrode (2) has a discontinuous structure made of an electrically conductive material, such as stainless steel, ferrous materials, materials non-ferrous materials such as aluminum, copper, tungsten, silver, gold, carbon, conductive polymers naturally conductive or charged with conductive particles.
    [0007]
    7. “OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to the preceding claim, characterized in that said active electrode (2) consists of a mesh, or a perforated plate or any semi-continuous structure with sufficiently openings large to allow the transmission of UV light.
    [0008]
    8. “EYE IOPHORESIS DEVICE FOR THE ADMINISTRATION OF ANY IONIZED MEDICINAL SOLUTION”, according to claim 6, characterized in that the said active electrode (2) consists of a part in continuous transparent plastic that, on the side of the reservoir (8), it is equipped with a plated mesh or thin plated lines of conductive materials.
    [0009]
    9. "EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to any of the preceding claims, characterized in that said active electrode (2) is connected to a direct current generator adapted to supply a direct current at 0.5 at 2 mA at a voltage adapted to the body and impedance of the riboflavin solution; said generator, in turn, being connected to said passive return electrode placed somewhere in the body to close the electrical circuit.
    [0010]
    10. “EYE IOPHORESIS DEVICE FOR THE ADMINISTRATION OF ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized by being placed at a distance of 1 to 6 mm in the central cornea, or preferably at a distance of 4 to 5 mm.
    [0011]
    11. "EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claim 1, characterized in that the electrode structure is a mesh or a surface comprising a sufficient number of holes so that the electrode is semitransparent to UV in the appropriate wavelength of 365 nm.
    [0012]
    12. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that the electrode structure has an annular shape, with a divergent transparent lens in its center (10) allowing a lighting surface with a diameter of 8 mm at a distance of 10 mm.
    [0013]
    13. "EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claim 1, characterized in that the electrode structure is a disk, surrounded by a divergent annular lens (10) allowing an illumination surface of 8 mm diameter at a distance of 10 mm; the lens (10) being placed around the electrode, the electrode surface is not impeded.
    [0014]
    14. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that the electrode structure is a 10 mm diameter disk, surrounded by a divergent annular lens (10), allowing a surface of illumination with a diameter of 8 mm at a distance of 10 mm, the device having walls placed with an alpha angle.
    [0015]
    15. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized by having a circular shape with an inner diameter of 8-12 mm, preferably 10 mm, made of non-electrically conductive materials, such as plastic.
    [0016]
    16. “OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized by having its proximal side adapted to be placed in contact with the cornea or the limbus on the periphery of the cornea; said proximal side being made of a different material, such as an elastomeric material, to accommodate small changes in the geometry of the eye so that it can fit perfectly to the surface of the eye preventing fluid leakage.
    [0017]
    17. "OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claim 1, characterized in that the reservoir (8) has an annular shape and on the periphery of the device a second circular wall is provided with an open end on the side the eye and a closed end on the electrode side, so as to form an outer annular chamber (3) for the reservoir (8); further being provided with means (4, 5, 6) to form a vacuum in the outer annular chamber to hold the device in place in the eye during application.
    [0018]
    18. "EYE PHOTOGRAPHY DEVICE FOR THE ADMINISTRATION OF ANY IONIZED MEDICINAL SOLUTION", according to the preceding claim, characterized in that the distal surface of said annular chamber (3) corresponds to the flat area of the eye, with an internal diameter of 12 mm and an external diameter of 18 mm, preferably 16 mm, or more preferably 14 mm.
    [0019]
    19. "OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claims 12 or 13 or 14, characterized by the transparent plastic material, such as polymethacrylate, polycarbonate, cycloolefin, polymethylpentene, polystyrene, to be used to configure a divergent or convergent lens (10) allowing central corneal illumination with a diameter of 8 to 10 mm.
    [0020]
    20. “OCULAR IONTOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that the device has a structure with walls that, together with the active electrode (2), form a reservoir (8) with an open end that is in contact with the eye and a closed end where the active electrode (2) is located.
    [0021]
    21. "EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION", according to claim 1, characterized by having means (4, 5, 6) to purge the reservoir (8) of its contents.
    [0022]
    22. “EYE IOPHORESIS DEVICE FOR THE ADMINISTRATION OF ANY IONIZED MEDICINAL SOLUTION”, according to claim 14, characterized in that the alpha angle is between 60 ° and 20 °, preferably between 30 ° and 20 ° to avoid a refraction of light excessive incident.
    [0023]
    23. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that the distance between the electrode itself and the surface of the eye is modifiable to control the pH value in the eye, since during the iontophoresis the pH increases only in the vicinity of the electrode and thus away from the eye surface.
    [0024]
    24. “EYE IOPHORESIS DEVICE FOR ADMINISTERING ANY IONIZED MEDICINAL SOLUTION”, according to claim 1, characterized in that at least one of the walls of the inner wall (1) and / or the wall of the annular chamber (3) are made with a non-transparent material to the treatment wavelength given to avoid irradiation from the corneal periphery or limbic structure.
    类似技术:
    公开号 | 公开日 | 专利标题
    BR112013010050B1|2021-03-30|EYE IOPHORESIS DEVICE TO ADMINISTER ANY IONIZED MEDICINAL SOLUTION
    JP2014503317A5|2014-03-27|
    ES2590127T3|2016-11-18|Corneal administration of iontophoresis crosslinking agents for the treatment of keratoconus and related ophthalmic compositions
    ES2283628T3|2007-11-01|MEDICINES SUPPLY DEVICE FOR TRANSPALPEBRAL IONTOPHORESIS.
    JP4308353B2|2009-08-05|Intraocular device of active substance by ion permeable treatment
    US7151960B1|2006-12-19|Dilation enhancer with pre-mediated contact lenses
    PT1434623E|2008-07-07|Device for medicine delivery by intraocular iontophoresis or electroporation
    AU2009219426B2|2015-12-03|Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
    WO2012162459A1|2012-11-29|Device and method for administering eye medications
    CA2851331C|2019-11-12|Improved cross-linking composition delivered by iontophoresis, useful for the treatment of keratoconus
    Matsuo et al.2017|Subretinal implantation of Okayama University-type retinal prosthesis | in canine eyes by vitrectomy
    JPH09266954A|1997-10-14|Therapy machine with electrode
    RU2612121C1|2017-03-02|Silicone hydrogel therapeutic soft contact lens
    WO2022026720A1|2022-02-03|Hydrogel ionic circuit based devices for electrical stimulation and drug therapy
    MXPA99000311A|2000-07-01|Device for the intraocular transfer of active products through iontofore
    同族专利:
    公开号 | 公开日
    RS54114B1|2015-12-31|
    KR101669715B1|2016-10-27|
    MX2013004511A|2013-05-30|
    KR20130139314A|2013-12-20|
    WO2012095876A1|2012-07-19|
    BR112013010050B8|2021-06-22|
    JP2014503317A|2014-02-13|
    AU2011355093A1|2013-06-27|
    BR112013010050A2|2020-10-20|
    EA201390571A1|2013-11-29|
    PT2648663E|2015-07-29|
    IL226703A|2017-06-29|
    ES2539717T3|2015-07-03|
    EP2648663A1|2013-10-16|
    EP2648663B1|2015-03-25|
    MX347934B|2017-05-18|
    EA022306B1|2015-12-30|
    US20130178821A1|2013-07-11|
    US9700456B2|2017-07-11|
    CA2814874A1|2012-07-19|
    AR085781A1|2013-10-30|
    CA2814874C|2017-10-10|
    JP5845286B2|2016-01-20|
    CN103167850B|2015-11-25|
    CN103167850A|2013-06-19|
    AU2011355093B2|2015-11-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US3122137A|1961-10-30|1964-02-25|Erlanger Gustav|Device for facilitating iontophoresis treatment of eyes|
    US4564016A|1982-05-24|1986-01-14|The Board Of Trustees Of The Leland Stanford Junior University|Apparatus for introducing ionized drugs into the posterior segment of the eye and method|
    FR2773320B1|1998-01-05|2000-03-03|Optisinvest|DEVICE FOR INTRAOCULAR TRANSFER OF ACTIVE PRODUCTS BY IONTOPHORESIS|
    IL123290A|1998-02-13|2001-12-23|Hadasit Med Res Service|Iontophoretic device|
    US6319240B1|1999-05-25|2001-11-20|Iomed, Inc.|Methods and apparatus for ocular iontophoresis|
    FR2830767B1|2001-10-12|2004-03-12|Optis France Sa|DEVICE FOR DELIVERING DRUGS BY IONTOPHORESIS OR INTROCULAR ELECTROPORATION|
    US7479133B2|2003-06-30|2009-01-20|Johnson & Johnson Consumer Companies, Inc.|Methods of treating acne and rosacea with galvanic generated electricity|
    FR2869531B1|2004-04-30|2006-07-14|Optis France Sa Sa|OCULAR IONTOPHORESIS DEVICE REDUCING IRRITATION|
    KR20080018980A|2004-04-30|2008-02-29|아이게이트 파르마 에스아에스|Irritation-reducing ocular ionthophoretic device|
    CA2632183A1|2005-08-25|2007-03-01|Philip R. Houle|Treatment systems for delivery of sensitizer solutions|
    US8545487B2|2007-12-05|2013-10-01|Avedro Inc.|Eye therapy system|
    JP2012502668A|2008-09-19|2012-02-02|アヴェドロ・インコーポレーテッド|Eye treatment system|
    JP2011525916A|2008-06-25|2011-09-29|エフイー３メディカル，インコーポレイテッド|Patches and methods for transdermal delivery of therapeutically effective amounts of iron|
    IT1393402B1|2008-08-28|2012-04-20|Sooft Italia Spa|USE OF ENHANCER EVENTUALLY WITH RIBOFLAVIN, AS WELL AS RELATIVE OPHTHALMIC COMPOSITIONS FOR CORNEAL CROSS-LINKING OF KERATOCON OR OTHER ECNEASIC CORNEAL PATHOLOGIES|US9622911B2|2010-09-30|2017-04-18|Cxl Ophthalmics, Llc|Ophthalmic treatment device, system, and method of use|
    WO2012154627A2|2011-05-06|2012-11-15|California Institute Of Technology|Light delivery device and related compositions, methods and systems|
    WO2013028833A1|2011-08-23|2013-02-28|Anthony Natale|Systems and methods for treating pathogenic infection|
    US9023092B2|2011-08-23|2015-05-05|Anthony Natale|Endoscopes enhanced with pathogenic treatment|
    WO2013149075A1|2012-03-29|2013-10-03|Cxl Ophthalmics, Llc|Compositions and methods for treating or preventing diseases associated with oxidative stress|
    US20150246215A1|2012-12-25|2015-09-03|Teikoku Seiyaku Co., Ltd.|Iontophoresis patch|
    WO2014210152A2|2013-06-25|2014-12-31|TECLens, LLC|Apparatus for phototherapy of the eye|
    ITVE20130043A1|2013-07-31|2015-02-01|I A C E R S R L|OPHTHALMOLOGICAL PERFECT DEVICE FOR THE TREATMENT OF CORNEAL DISEASES SUCH AS THE KERATOCONO.|
    US10828506B2|2013-10-30|2020-11-10|Alcon Inc.|Crosslinking control|
    EP3134042A2|2014-04-23|2017-03-01|Seros Medical, LLC|Vacuum-assisted drug delivery device and method|
    US9931199B2|2014-05-05|2018-04-03|Roberto Gustavo ALBERTAZZI|Methods and apparatus for treating keratoconus|
    JP5828535B1|2014-10-10|2015-12-09|石根 三井|Contact lenses for straightening corneal cross-linking|
    ES2874562T3|2014-12-19|2021-11-05|Kemin Ind Inc|Intraocular delivery of bioactive molecules through the use of iontophoresis|
    WO2016106217A1|2014-12-22|2016-06-30|TECLens, LLC|Corneal crosslinking with oxygenation|
    CA2973595A1|2015-01-22|2016-07-28|Eyegate Pharmaceuticals, Inc.|Iontophoretic contact lens|
    EP3324973B1|2015-07-21|2020-06-03|Avedro, Inc.|Treament of an eye with a photosensitizer|
    AU2016379263A1|2015-12-22|2018-07-19|Mitsui Medical Commerce Co., Ltd.|Contact lens for corrective corneal crosslinking and method for producing same|
    US10342697B2|2016-04-13|2019-07-09|Avedro, Inc.|Systems and methods for delivering drugs to an eye|
    RU2635454C1|2016-11-18|2017-11-13|Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт глазных болезней"|Method for purulent corneal ulcers treatment|
    US20210259883A1|2018-06-20|2021-08-26|Optotek D.O.O.|An acoustic diverter for improved safety during ophthamlmic laser treatments|
    RU2698041C1|2018-07-11|2019-08-21|Государственное бюджетное учреждение "Уфимский научно-исследовательский институт глазных болезней Академии наук Республики Башкортостан"|Method of producing xenograft with modifiable stiffness parameters for ophthalmosurgery|
    RU2697631C1|2018-08-30|2019-08-19|федеральное государственное автономное учреждение "Национальный медицинский исследовательский центр "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации|Method for intraoperative keratoprotection in phacoemulsification|
    IT201900010341A1|2019-06-27|2020-12-27|Vision Eng Italy Srl|Device, system and method of treatment of a corneal tissue|
    WO2022026720A1|2020-07-31|2022-02-03|Board Of Regents Of The University Of Nebraska|Hydrogel ionic circuit based devices for electrical stimulation and drug therapy|
    法律状态:
    2020-11-03| B06F| Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]|
    2020-11-10| B06U| Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]|
    2021-02-17| B09A| Decision: intention to grant [chapter 9.1 patent gazette]|
    2021-03-30| B16A| Patent or certificate of addition of invention granted|Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 30/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
    2021-06-22| B16C| Correction of notification of the grant|Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/01/2011, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO |
    优先权:
    申请号 | 申请日 | 专利标题
    PCT/IT2011/000009|WO2012095876A1|2011-01-12|2011-01-12|Device and method for corneal delivery of riboflavin by iontophoresis for the treatment of keratoconus|
    [返回顶部]